Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-03
DOI
10.1038/s41598-020-78342-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels
- (2020) Changxi Chen et al. BIOSCIENCE REPORTS
- Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer
- (2020) Wei Chen et al. Hepatology International
- The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
- (2020) Divya P. Kumar et al. Scientific Reports
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Treatment options for nonalcoholic fatty liver disease
- (2019) Amir Anushiravani et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- A novel heterozygous ABCB 4 , RUNDC 3B and ABCB 1 deletion associated with severe cholestatic liver disease in adulthood
- (2019) Benedetta Terziroli Beretta‐Piccoli et al. HEPATOLOGY
- Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels
- (2019) Samer Gawrieh et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
- (2019) Jung Il Lee et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial
- (2019) Nimisha Jain et al. Scientific Reports
- Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients
- (2018) Harshit Garg et al. Surgery for Obesity and Related Diseases
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
- (2017) Baek Gyu Jun et al. PLoS One
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
- (2016) Ivana Mikolasevic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
- (2015) Sanjay Chatterjee et al. Scientific Reports
- The Diagnostic Accuracy of Transient Elastography for the Diagnosis of Liver Fibrosis in Bariatric Surgery Candidates with Suspected NAFLD
- (2014) Sylvie Naveau et al. OBESITY SURGERY
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
- (2009) Vincent Wai-Sun Wong et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now